Found 7,314 articles
AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency
AltruBio Inc. announced that AltruBio President and CEO Judy Chou, Ph.D., has been appointed to the Independent Citizens’ Oversight Committee, the governing Board of the California Institute for Regenerative Medicine.
SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease
SomaLogic, a leader in AI data-driven proteomics technology, announced findings from key studies demonstrating the broad and deep role proteomics plays in detecting cardiovascular risk, achieving optimal cardiometabolic health, and assessing the correlation of cardiovascular disease with other diseases that are among the leading causes of death around the world.
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
Scorpion Therapeutics, Inc. announced preclinical proof-of-concept data for STX-721, the Company’s first development candidate from its STX-EGFR-EXON-20 program. STX-721 is a next-generation, orally delivered therapy, designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors, a well-known, clinically validated oncogenic driver in non-small cell lung cancer.
Prime Medicine Announces Closing of Upsized Initial Public Offering
Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share.
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3rd
Kymera Therapeutics, Inc. will report third quarter 2022 financial results on November 3, 2022 and will host a conference call at 8:30 a.m. ET that day.
Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
Kyverna Therapeutics today announced the filing of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for KYV-101, a novel therapy for the treatment of lupus nephritis.
Interviews can be difficult in any field, but especially in a competitive industry like the life sciences. Read on to discover the best way to answer salary interview questions in our guide.
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
Kyverna Therapeutics ("Kyverna"), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Peter K. Maag, Ph.D., as the company's chief executive officer (CEO).
Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies
Metagenomi announced that it has opened a new, in-house Good Manufacturing Practices facility, based within its 50,000 square foot campus in Emeryville, California.
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Ray Therapeutics and Forge Biologics announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis pigmentosa.
The life science industry is vast, and there are ample opportunities. Here are some of the highest-paying jobs you can get with a biology degree as well as a brief overview of what each job entails.
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
LEXEO Therapeutics, Inc. announced new clinical data from its ongoing study of LX1001 for APOE4-associated Alzheimer’s disease will be presented at the 29th European Society of Gene and Cell Therapy Annual Meeting, which is being held live in Edinburgh, Scotland and virtually from October 11-14, 2022.
Clinical Research Associates are almost always in high demand. Use these tips to create the best clinical research resume or CV to land your dream job.
AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference
AltruBio Inc. announced that AltruBio President and CEO Dr. Judy Chou will speak on “The Next Wave of Targeted Therapies” at the Longwood Healthcare Leaders Fall Webconference on Wednesday, September 21, 2022.
Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022
Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total funding raised to date to $330 million.
Fierce Biotech Names Synthekine as One of Its “Fierce 15” Biotech Companies of 2022
Synthekine Inc. , an engineered cytokine therapeutics company, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
Visus Therapeutics to Present at the Baird 2022 Global Healthcare Conference
Visus Therapeutics, Inc. announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13th, 2022, at the InterContinental New York Barclay hotel.
Neomorph, Inc. Announces Appointment of Chief Financial Officer
Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ‘undruggable targets,’ announced the appointment of Bell Zhong as the company’s Chief Financial Officer.